ArticleFrontiers in cellular and infection microbiology2026
A machine learning-based online prediction model for recurrence risk in patients with
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Methods: This multicenter retrospective study included 829 KPLA patients from three tertiary hospitals (2016-2024). Data of 722 patients from the Affiliated Hospital of Chengde Medical University and Kailuan General Hospital were divided into a training set (n = 506) and an internal testing set (n = 216), and the data of the 107 patients from the First Hospital of Qinhuangdao were included in the quasi-external validation set. Twenty-four candidate variables were collected, and 9 key predictors were retained based on the results of univariate analysis, Least Absolute Shrinkage and Selection Operator regression, and the Boruta algorithm. After constructing seven machine learning models, with the logistic regression model (LM) as the baseline control, through accuracy and area under the curve (AUC), decision curve analysis, and calibration curve analysis, the extreme gradient boost method (XGBoost) was selected as the final prediction model. SHAP (SHapley Additive exPlanations) analyses were conducted to enhance model interpretability, and a web-based tool was developed for use in clinical practice. Results: The hyperparameter-optimized XGBoost model showed optimal performance, with AUC values of 0.936 (95% CI: 0.914-0.959), 0.868 (95% CI: 0.799-0.938), and 0.904 (95% CI: 0.819-0.988) in the training, internal testing, and quasi-external validation sets, respectively. The intersection results of the three abovementioned feature selection approaches yielded 9 key predictors, including age, type 2 diabetes mellitus, malignant neoplasm, biliary disease, fibrinogen level, procalcitonin level, multiple abscesses, septic shock, and Sequential Organ Failure Assessment (SOFA)-2 score. The web-based tool enabled to assess individualized recurrence risk. Conclusions: The XGBoost-based prediction model integrates clinical and laboratory indicators to accurately predict KPLA recurrence risk, with good generalizability and interpretability. The accompanying web-based tool provides a practical decision-making application for clinicians to identify high-risk patients early and implement personalized interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.